Novo makes semaglutide in engineered yeast; synthetic makers build it chemically. What FDA and EMA documents say about impurities, generics and compounding.
Retatrutide isn't approved. Here's what FDA warning letters, Lilly's lawsuits, poison centers and regulator lab tests found in grey-market vials as of Oct 2026.
How to read a GLP-1 trial on ClinicalTrials.gov, using STEP 1: NCT numbers, primary outcomes, estimands, the results tab, and how to spot outcome switching.
JAMA Network Open published findings from investigators who submitted intake forms to 49 telehealth GLP-1 platforms. 45 prescribed. Two-thirds with no docu
The WHO 2026 obesity guidance update — what changed from prior versions, what the new recommendations actually say about GLP-1s, and how they
Weight Regain After Stopping GLP-1s: What STEP 1 Extension and Real-World Data Show
A Nature Aging publication reported a 2.4-year reduction in GrimAge2 epigenetic clock scores after 52 weeks of semaglutide. What epigenetic clocks actually
A review of what the dermatology literature establishes about diffuse hair shedding after rapid weight loss, and how it applies to GLP-1 therapy.
The SYNERGY-NASH trial results on tirzepatide for metabolic dysfunction-associated steatohepatitis — what the data showed and what it means for MASH treatment.
Boehringer Ingelheim
Survodutide (BI 456906) is Boehringer Ingelheim
The SURMOUNT-MMO trial
SURMOUNT-5 is the only direct head-to-head RCT comparing semaglutide 2.4mg vs tirzepatide 15mg. Here
SUMMIT showed tirzepatide improved exercise capacity and reduced heart failure events in HFpEF patients with obesity. Full results and implications sourced.
STEP-HFpEF: Semaglutide for Heart Failure With Preserved Ejection Fraction
The STEP-HFpEF follow-up data on semaglutide for obese patients with heart failure with preserved ejection fraction — what changed and what the data means.
State-by-State GLP-1 Prescribing Rules: Where Telehealth Hits Legal Walls in 2026
Pfizer
The 2026 evidence landscape for combining semaglutide with SGLT2 inhibitors — trials, subgroup data, and what combining the two classes actually delivers.
Semaglutide 7.2mg (3x the approved Wegovy dose) showed 20.7% weight loss in STEP-UP 1. Full efficacy data, safety signals, and timeline to approval.
The 2026 interim readout from retatrutide
Clinical trials show 15-25% weight loss. Real-world data shows 5-12%. The gap isn
Real-World GLP-1 Adherence: Why 50% of Patients Quit Within a Year
Trial data was generated under controlled conditions. Claims databases, EHR networks, and FAERS are telling a different story: 68% real-world adherence vs.
Prior authorization for GLP-1 weight loss medications is denied 30-60% of the time depending on insurer. Published data on approval rates, appeal success, and workarounds.
Reading the placebo arms of the major GLP-1 obesity trials as evidence in their own right about what structured lifestyle intervention produces.
The STEP TEENS trial found semaglutide reduced BMI by 16.1% in adolescents at 68 weeks. Tirzepatide
Novo Nordisk
A reading of Novo Nordisk
Novo Nordisk vs. Eli Lilly: The $200 Billion GLP-1 Market War in Charts
Novo Nordisk
GLP-1 users without exercise lose ~38% of weight loss as lean mass. The Lundgren 2021 RCT showed exercise + liraglutide reduced lean mass loss by 40% versu
The CMS demonstration program launched July 1, 2026, creating the first Medicare pathway for GLP-1 obesity treatment. Eligibility requirements, cost-sharin
A review of what trial evidence exists — and mostly does not exist — for continuing GLP-1 therapy at a reduced maintenance dose after weight loss.
What body-composition substudies using DEXA actually measured about fat mass and lean mass during semaglutide and tirzepatide treatment.
A landmark Lancet review confirms GLP-1s have direct protective effects on hearts, kidneys, livers, and brains.
A patient-oriented reading of Judge Mark Pittman
Among eligible patients with T2D and obesity, GLP-1 prescribing rates: 18.4% for non-Hispanic White patients, 9.6% for non-Hispanic Black patients. A syste
Semaglutide and other GLP-1 receptor agonists reduce alcohol intake in animal models and real-world data. Here
What age-stratified subgroup analyses of the major GLP-1 trials report about efficacy and safety in older adults, and where the evidence thins out.
Semaglutide patents expire 2032-2035. Tirzepatide patents extend further. Here
The 2026 meta-analyses on GLP-1s and pancreatitis risk — what the pooled data shows, how it changes over follow-up, and what the label language reflects.
Semaglutide significantly reduced knee pain in arthritis patients. Weight loss gives joints a second chance.
Muscle Loss on GLP-1s: How Much Is Normal, and What Actually Prevents It
Three major 2026 publications reframe the GLP-1 muscle loss debate: relative muscle mass improves, liver mass loss exceeds muscle loss, and mitochondrial proteins increase. Evidence-based…
Semaglutide
A review of the trial evidence linking GLP-1 receptor agonists to steatotic liver disease outcomes, including the ESSENCE results and their limits.
Gastric emptying delayed ~40%. The downstream effect on oral contraceptive Cmax, levothyroxine absorption timing, warfarin INR stability, and the weight-lo
What the 12-month follow-up studies on GLP-1 discontinuation actually show about weight regain patterns.
SELECT: 20% MACE reduction in non-diabetic obesity (HR 0.80). FLOW: 24% composite kidney endpoint reduction, stopped early for overwhelming benefit. SURPAS
GLP-1 and Cancer Risk: The Epidemiological Evidence (Positive and Concerning)
Neuroimaging studies reveal how semaglutide and tirzepatide alter brain reward circuitry, appetite centers, and food cue responses. Every published study compiled.
STEP-1 DEXA substudy found -1.4% hip BMD vs. -0.5% placebo at 68 weeks. Tirzepatide showed -0.4% despite greater weight loss. A systematic review of what t
A review of real-world claims and pharmacy data on GLP-1 persistence, the reasons patients stop, and why trial adherence and real-world adherence diverge.
GLP-1 and Addiction: The Emerging Signal From Alcohol, Nicotine, and Opioid Data
A review of the trial and meta-analytic evidence on gallbladder and biliary disease during GLP-1 receptor agonist therapy, and how to separate drug effect from weight-loss effect.
Foundayo (Orforglipron): The First Small-Molecule GLP-1 — Complete Phase 3 Data
The FLOW trial
The June 29 Deadline: What the FDA
How to read the FDA Adverse Event Reporting System (FAERS) data on GLP-1s — what the numbers actually mean and their limits as a signal.
Approval timelines, safety labeling differences (pancreatitis, thyroid C-cell), the absence of a 503B-equivalent in EU law, and how national HTA bodies lik
Pfizer
A review of the randomized dose-ranging evidence for semaglutide, including where the efficacy curve flattens and where the tolerability curve steepens.
50-70% of GLP-1 patients discontinue within the first year. Here
A review of the randomized withdrawal and extension data on what happens to body weight after semaglutide and tirzepatide are stopped.
Danuglipron: The Rise and Fall of Pfizer
Pfizer discontinued danuglipron, its first oral GLP-1. Here
The Institute for Clinical and Economic Review
The Compounding Litigation Map: Every Novo Nordisk and Lilly Lawsuit Against GLP-1 Compounders
A review of the published analytical testing, regulatory reporting and adverse-event data on compounded semaglutide preparations, and what remains unmeasured.
SURMOUNT-5 is the only randomized head-to-head trial: -20.2% vs. -13.7% body weight at 72 weeks favoring tirzepatide. The full results table, the cardiovas
A complete census of multi-mechanism GLP-1 combinations in clinical development: dual agonists, triple agonists, and peptide combinations in Phase 2+.
CagriSema combines cagrilintide (an amylin analog) with semaglutide. REDEFINE trial data shows 22-25% weight loss at 68 weeks. Full data tables and analysis.
ASCO 2026 included a 1.3M-patient claims analysis showing reduced incidence of 13 obesity-associated cancers in GLP-1 users. The hazard ratio data — and th
Cancer prevention, improved immunotherapy outcomes, breast cancer risk reduction — ASCO 2026
A review of the neuroimaging literature on GLP-1 receptor agonists, food cue reactivity, and the mechanisms behind reduced
Amycretin: Novo
The June 29, 2026 closure of the public comment period on FDA
503A and 503B were created by the Drug Quality and Security Act of 2013 after the NECC outbreak killed 64 people. A statutory comparison of the two framewo
ADA, AACE, and The Obesity Society updated their obesity treatment guidelines in 2025-2026. What changed, where they agree, and where they diverge.
The 2026 American Diabetes Association consensus statement on GLP-1s in type 2 diabetes management — what changed and what it recommends.
Smart step-down protocols preserve most weight loss. The Lancet 2026 maintenance data explained.
A comprehensive comparison of Mounjaro/Zepbound (tirzepatide) vs Ozempic/Wegovy (semaglutide). Weight loss data, side effects, mechanisms, and which might work better for you.
Survodutide Phase 2 NEJM data: 83% MASH improvement, 87% liver fat reduction, 64.5% fibrosis improvement. Glucagon mechanism explained. Phase 3 trials for obesity and liver disease underway.
The first direct comparison trial: tirzepatide lost 20.2% vs. semaglutide
The FDA
Stanford identifies a drug that may help preserve muscle during GLP-1 weight loss. The PNAS June 2026 study.
A week-by-week guide to Ozempic and Wegovy side effects. When nausea peaks, when it fades, and what symptoms warrant calling your doctor.
FDA approves semaglutide for MASH with liver fibrosis. Breaking down the ESSENCE trial data: 63% resolution of steatohepatitis, 37% fibrosis improvement.
Wegovy becomes the first GLP-1 approved for fatty liver disease (MASH). ESSENCE trial showed 63% achieved resolution of liver inflammation vs 34% on placebo.
The first placebo-controlled trial of semaglutide for alcohol use disorder shows reduced drinking, cravings, and heavy drinking days. Full study breakdown.
The SELECT trial proved semaglutide reduces cardiovascular events in people without diabetes. Full analysis of the landmark study that changed GLP-1 treatment.
Cross-trial comparison of retatrutide (TRIUMPH-1), tirzepatide (SURMOUNT-1), and semaglutide (STEP-1) Phase 3 data. Efficacy, safety, and cardiometabolic outcomes.
Retatrutide is Lilly
Retatrutide targets GLP-1, GIP, and glucagon receptors simultaneously. Phase 2 data: 24.2% body weight loss at 48 weeks, 86% achieved normal liver fat. Here
Eli Lilly
Protein requirements on Ozempic and Wegovy: research-based recommendations, how to hit targets when appetite is suppressed, and why it matters for muscle.
Pemvidutide is a GLP-1/glucagon dual agonist developed by Altimmune that received FDA Breakthrough Therapy designation for MASH in January 2026. Its glucagon-mediated fat oxidation…
Altimmune
Weight loss plateaus on GLP-1 medications are normal, typically hitting around week 60. Here
GLP-1 medications carry a black box warning for thyroid cancer based on rodent studies. Here
A week-by-week guide to GLP-1 side effects. When nausea starts, peaks, and resolves. When to call your doctor. What
Up to 15-23% of people don
FDA approves semaglutide for chronic kidney disease in type 2 diabetes. FLOW trial showed 24% reduced risk of kidney failure. Full trial analysis.
Will Ozempic cause loose skin? We explain
Ozempic face refers to facial sagging and hollowing from rapid weight loss. Here
Why women on GLP-1 medications are reporting unexpected pregnancies. The science behind fertility restoration, birth control absorption, and what you need to know.
Why are women getting pregnant on Ozempic? We explain the science behind restored fertility, birth control concerns, and what the research shows.
The Ozempic baby boom is real. Here
Orforglipron is Lilly
Eli Lilly
Oral Wegovy launched January 2026 at $149/month. Five months in, here
The FDA approved oral Wegovy in December 2025 based on OASIS 4 data: 16.6% weight loss at 64 weeks. Complete trial results, comparisons to injectable, and what it means for patients.
From Rybelsus (2019) to Foundayo (2026): how oral GLP-1 development reached the tipping point.
Nature Metabolism study reveals the exact neuronal pathway — a breakthrough for more precise GLP-1 therapy.
The Medicare GLP-1 Bridge program ($50/month copay, July 2026) represents the largest government investment in obesity pharmacotherapy. Cost-benefit analysis with CBO projections and…
CMS fact-checked: eligible drugs, qualifying conditions, enrollment process, timeline for July 2026 launch.
CMS announced the BALANCE Model in December 2025 to expand GLP-1 access through Medicare and Medicaid. Copays capped at $50/month. Medicaid launch expected May 2026, Medicare Part D January…
A May 2026 retrospective cohort study in J Med Internet Res found patients receiving GLP-1 medications through telehealth without nutritional support lost
Wegovy costs $1,349/month in the US, under $200 in Germany, and as little as $40 in India. Here
GobyMeds offers compounded semaglutide from $99/month and tirzepatide from $133/month with no membership, free consultation, and free overnight shipping. Full 2026 review.
GLP-1 medications aren
An honest look at the unanswered questions about GLP-1 medications. What the long-term data is missing and what we
Practical nutrition guidance for Ozempic, Wegovy, and Mounjaro. What to eat, what to avoid, and how to maximize results while minimizing side effects.
A practical 7-day meal plan for your first week on Ozempic, Wegovy, or Mounjaro. Nausea-friendly foods, protein priorities, and easy recipes.
Comparing GLP-1 medications to bariatric surgery. Outcomes, reversibility, costs, and how to decide which approach is right for you.
How does GLP-1 medication compare to gastric bypass and sleeve gastrectomy? We compared weight loss outcomes, costs, risks, recovery time, and long-term data.
What we know (and don
Retatrutide targets three receptors: GLP-1, GIP, and glucagon. How triple agonism could deliver even greater weight loss than current medications.
How to travel with Ozempic, Wegovy, or Mounjaro. TSA rules, temperature storage, and international considerations.
Separating fact from fiction on the most viral GLP-1 claims. What the science actually says about common Ozempic myths.
GLP-1 drugs slow gastric emptying, raising concerns about aspiration during anesthesia. The ASA updated its guidelines in 2023. Here
The dreaded sulfur burps on GLP-1 medications. Why they happen, foods that trigger them, and proven strategies to reduce or eliminate this embarrassing side effect.
Not losing weight on GLP-1 medication? 10-15% of patients are slow or non-responders. Here
Practical, evidence-based strategies for managing nausea, constipation, and other common GLP-1 side effects. What works and what doesn
When to inject Ozempic or Mounjaro with irregular work hours. Practical guidance for nurses, factory workers, and anyone with rotating or night shifts.
Complete review of GLP-1 safety signals: pancreatitis, thyroid cancer, gastroparesis, NAION, hair loss, ED, and gallbladder events. Evidence quality assessed.
Are GLP-1 medications legit? We reviewed the clinical trial data, real patient outcomes, and what to realistically expect from semaglutide and tirzepatide for weight loss.
Cancer prevention, muscle protection, oral options, Medicare coverage — the most encouraging GLP-1 research of 2026.
GLP-1 receptors aren
The endogenous GLP-1 hormone has a 90-second plasma half-life. The pharmaceutical versions extend this to a week through fatty acid binding. A rigorous pha
Emerging evidence that GLP-1 weight loss may improve psoriasis severity. The obesity-inflammation-psoriasis connection and what patients are reporting.
Protein requirements while on Ozempic, Wegovy, or Mounjaro. How much to eat, best sources, and strategies for when appetite is low.
Can you use Ozempic or Wegovy after gastric sleeve or bypass? Evidence on weight regain treatment, safety considerations, and which post-bariatric patients are candidates.
How semaglutide and tirzepatide stay active for a week when natural GLP-1 lasts only minutes. The science of half-life, albumin binding, and steady-state levels.
How Ozempic and Wegovy work during perimenopause. Addressing hormonal weight gain, interactions with HRT, and what the research shows for women 40-55.
FDA-approved GLP-1 medications for adolescents 12+. STEP TEENS trial data, safety considerations, and what the AAP recommends for childhood obesity treatment.
Complete analysis of GLP-1 clinical trials in adolescents. STEP TEENS results, liraglutide pediatric data, and ongoing tirzepatide studies in children and teens.
Polycystic ovary syndrome affects 10% of women. GLP-1 drugs improve insulin resistance, reduce androgens, restore ovulation, and produce weight loss. Here
Head-to-head comparison of the major GLP-1 medications. Differences in weight loss, mechanism, dosing, side effects, and cost.
10-15% of people don
Complete guide to GLP-1 medications during and after menopause. HRT compatibility, targeting visceral fat, bone health monitoring, and cardiovascular benefits for postmenopausal women.
GLP-1 and MASLD/MASH: The Liver Disease Revolution Nobody
Both Eli Lilly and Novo Nordisk have committed billions to GLP-1 manufacturing expansion. How the production scale-up is progressing, what it means for supply and pricing, and the…
Semaglutide is FDA-approved for fatty liver disease. What the clinical data shows and who benefits.
Is combining a ketogenic diet with Ozempic or Mounjaro safe and effective? Potential benefits, risks, and practical considerations for keto on GLP-1 medications.
Insurance coverage for GLP-1 weight loss drugs varies dramatically by state, employer, and plan type. Some states mandate coverage; many Medicaid programs still exclude anti-obesity…
GLP-1 is a key messenger between your gut and brain. Understanding this communication system explains appetite, satiety, food noise, and why these medications work.
Semaglutide patents expire December 2031, tirzepatide January 2036. Generic liraglutide arrived in 2024. Full patent landscape, settlement details, biosimilar pathway, and international…
Rapid weight loss from any cause increases gallstone risk. GLP-1 drugs are no exception. Here
The constant mental chatter about food that vanishes on GLP-1 medications. What causes food noise, why some brains are louder, and how semaglutide silences it.
How to exercise while on Ozempic, Wegovy, or Mounjaro. Why resistance training is essential and how to optimize your workouts.
Evidence-based guide to Ozempic, Wegovy, and other GLP-1s for seniors. Clinical trial data on adults 65+, muscle loss prevention, and special considerations from the SELECT and FLOW trials.
STEP 1 extension data shows most patients regain weight after stopping semaglutide. Here
STEP-1 extension data: two-thirds of weight regained within 1 year of stopping semaglutide. Cardiometabolic improvements reversed proportionally. Evidence-based discontinuation analysis.
Fake Ozempic and Wegovy are circulating. How to identify counterfeit GLP-1 medications and protect yourself from dangerous fakes.
An honest analysis of GLP-1 medication costs vs benefits. What the health economics research says about value.
Compounded semaglutide stability: beyond-use dating requirements, peptide degradation pathways, storage conditions, and why 503B outsourcing facilities provide more reliable stability data…
Emerging research on semaglutide for cocaine and stimulant use disorders. What the science shows and what trials are underway.
GLP-1s show promise for fatty liver, but what about cirrhosis? Evidence, safety concerns, and why advanced liver disease requires special consideration.
Can cancer survivors safely use Ozempic or Wegovy? Evidence on GLP-1s after cancer treatment, weight management, and special considerations for cancer history.
Emerging May 2026 data suggests GLP-1 medications may be associated with improved breast cancer outcomes. Observational evidence, biological rationale, and research limitations assessed.
GLP-1 receptors are expressed throughout the brain. Emerging evidence suggests neuroprotective effects in Alzheimer
Can you use Ozempic or tirzepatide while preserving muscle? Body composition data, cutting phase strategies, and what bodybuilders need to know about GLP-1s.
GLP-1 medications access your brain directly. Understanding how they cross the blood-brain barrier explains appetite control, food noise reduction, and potential effects on addiction and…
New evidence shows GLP-1 medications reduce inflammation and improve organ health even before the scale moves.
GLP-1 medications aren
How Ozempic and Wegovy affect athletic performance, muscle mass, endurance, and recovery. WADA status, professional athlete considerations, and sports-specific guidance.
Meta-analysis of 40 RCTs: GLP-1 drugs significantly reduce CRP and TNF-alpha vs placebo and other diabetes drugs. Only 20-60% of CRP reduction is explained by weight loss. Complete…
From $1,400/month to $50-$245. How competition, policy, and oral options collapsed GLP-1 pricing.
STEP TEENS: semaglutide produced a 17% BMI reduction in adolescents aged 12-17 with obesity. 45% dropped below the clinical obesity threshold. NEJM 2022. Complete trial data and…
Complete analysis of the FLOW trial: semaglutide reduced major kidney events by 24%, CV events by 18%, and death by 20% in T2D patients with CKD. Full data and methodology.
The FLOW trial is the first dedicated kidney outcomes trial for a GLP-1 drug. Semaglutide cut major kidney events by 24%, cardiovascular death by 29%, and was stopped early for efficacy.
The FDA issued 80+ warning letters to GLP-1 compounders in 2025-2026. What the letters say, who was targeted, and what it means for your treatment.
The FDA resolved the semaglutide shortage in February 2025. Here
FDA GLP-1 compounding enforcement actions in 2026. Warning letters, 503A vs 503B legal status, shortage declarations, and which pharmacies are still operating legally.
On April 30, 2026, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List. Here
The FDA proposed excluding semaglutide, tirzepatide, and liraglutide from 503B compounding. Every claim sourced from the Federal Register and FDA statements.
The FDA cites 455+ adverse events from compounded semaglutide. What do the reports actually show? We source the data and provide context.
The Phase 3 ESSENCE trial showed semaglutide 2.4 mg resolved MASH in 62.9% of patients and improved liver fibrosis in 37%. Published in NEJM April 2025. FDA granted Priority Review for this…
Three threads from the Endocrine Society
In 2023, the EMA launched a safety review of GLP-1 drugs and suicidal ideation. In 2024, they concluded: no causal link found. Here
At least 8 new GLP-1 medications in development. What
We compiled compounded and brand-name GLP-1 pricing from verified provider websites. Every option ranked from cheapest to most expensive.
CagriSema produced 22.7% weight loss in REDEFINE 1. SURMOUNT-5 showed tirzepatide beats semaglutide head-to-head. What these trials mean for the future of obesity treatment.
Byetta (exenatide) was discontinued by AstraZeneca in October 2024. A generic version exists from Amneal. Here
Every way to save on GLP-1 weight loss medications in 2026. Brand-name pills from $149/mo, compounded injectables from $146/mo, and new savings programs.
The BELIEVE trial (NCT05616013), published in Nature Medicine March 2026, is the first randomized trial to demonstrate pharmacological muscle preservation during GLP-1 therapy. 507…
The FDA
Complete decoded breakdown of Zepbound vial pricing by dose, channel, and commercial structure.
FDA approved semaglutide 7.2mg on May 13, 2026. STEP UP trial: 20.7% weight loss, 1 in 3 achieving 25%+. The sourced data breakdown.
Complete timeline of Wegovy
Complete explainer on the TrumpRx federal drug portal and what it means for GLP-1 access.
Full analysis of TRIUMPH-1 Phase 3 topline data: retatrutide 4mg/9mg/12mg efficacy, cardiometabolic outcomes, safety signals, and regulatory timeline.
Deep evidence review of the SYNERGY-NASH trial of tirzepatide for MASH/NASH liver disease.
Deep evidence review of the SURPASS-CVOT trial of tirzepatide for diabetic cardiovascular disease.
SURMOUNT-OSA: Tirzepatide for Obstructive Sleep Apnea — Complete Trial Data
Evidence review of the complete STEP clinical trial program for semaglutide weight management.
Evidence review of the STEP HFpEF trial of semaglutide for heart failure with preserved ejection fraction.
Active state AG investigations into GLP-1 telehealth companies and what they mean for the industry.
Sprout Health tirzepatide pricing for 2026: what you
Sprout Health offers compounded semaglutide at $249/month and tirzepatide at $299/month with locked pricing at any dose. Full 2026 review covering cost, process, and legitimacy.
SURMOUNT-5 trial data compared: tirzepatide achieved 20.2% weight loss vs semaglutide
Full timeline for when generic semaglutide actually arrives at U.S. retail pharmacies.
Deep evidence review of the SELECT cardiovascular outcomes trial and its extended follow-up.
Complete map of the authorized telehealth partnerships for Wegovy and Zepbound distribution.
Evidence review of retatrutide phase 2 data and the TRIUMPH phase 3 program.
Complete analysis of Eli Lilly
Complete reference on retail pharmacy cash-pay pricing for GLP-1 medications in 2026.
Explainer on PBM rebate economics and how they affect GLP-1 copays vs cash-pay pricing.
GLP-1 weight loss plateaus are normal and documented in every major trial. Here
Eli Lilly
Evidence review of orforglipron
Oral semaglutide, orforglipron (Foundayo), and amycretin compared. Efficacy, pricing, mechanism, and what the pill revolution means for GLP-1 access.
What Novo Nordisk and Eli Lilly
2026 GLP-1 revenue forecasts for Novo Nordisk and Eli Lilly, with Wegovy and Zepbound breakdowns.
Inside the March 9, 2026 Novo Nordisk-Hims & Hers settlement that ended the compounded semaglutide war.
Full breakdown of the Medicare 71% Ozempic discount and what it means for 2027 GLP-1 access.
International GLP-1 price arbitrage analysis — what channels remain economically meaningful in 2026.
How the HRSA 340B program creates a hidden GLP-1 pricing channel through hospitals and FQHCs.
Complete guide on when to pause or stop semaglutide and tirzepatide. Covers pre-surgery protocols, pregnancy planning, adverse events, weight plateaus, and what happens when you stop.
What the research shows about semaglutide and NAION (nonarteritic anterior ischemic optic neuropathy). The JAMA study, FDA FAERS data, risk factors, and what you should watch for.
The facts on semaglutide, tirzepatide and thyroid cancer risk. Understanding the FDA Black Box Warning, rodent studies vs human data, and who should not take GLP-1 medications.
Systematic reviews confirm GLP-1 drugs increase testosterone in obese men by 1.39 ng/mL on average. How it works, fertility implications, and every major study explained.
Complete guide to switching from semaglutide to tirzepatide or between GLP-1 providers: when to switch, dose conversion, avoiding gaps, and what to expect.
What happens when you stop Ozempic or Zepbound? The STEP-1 extension data on weight regain, tapering strategies, and when you actually need to stop permanently.
Can Ozempic help you quit smoking? We analyze the Annals of Internal Medicine study, active clinical trials, and the science behind GLP-1s and nicotine addiction.
Tirzepatide dramatically reduced sleep apnea severity in obese patients, potentially offering an alternative to CPAP. NEJM results show up to 63% AHI reduction.
Tirzepatide becomes the first medication ever approved to treat obstructive sleep apnea. What the SURMOUNT-OSA trial showed and what it means for 30 million Americans.
GLP-1 users report reduced compulsive shopping. No studies exist, but the dopamine science is intriguing. We separate anecdotes from theory.
People report their urge to shop has vanished on GLP-1 medications. Why dopamine-driven retail therapy may be the latest
Compounded semaglutide lasts 28-90 days. Brand-name Ozempic: 24 months. Oral Wegovy: no refrigeration needed. A sourced storage and shelf life reference.
People are reporting they quit smoking on Ozempic without trying. The science behind GLP-1s and nicotine addiction, plus active clinical trials.
222,942-patient study shows semaglutide users have 32% fewer tobacco-related medical encounters. Active trials, the dopamine mechanism, and what it means for smokers.
Complete guide to next-gen GLP-1 drugs: CagriSema, Amycretin, Survodutide, VK2735, and more. Efficacy rankings, mechanisms, timelines, and how they compare to current medications.
How semaglutide and tirzepatide are helping women with PCOS. The connection between insulin resistance, weight loss, and hormonal balance.
Lixisenatide stopped motor symptom progression in early Parkinson
The facts on semaglutide, tirzepatide and pancreatitis risk. Symptoms to watch for, who
What
A realistic timeline of your GLP-1 journey. What happens month 1, month 3, month 6, and beyond. Setting proper expectations.
Tirzepatide projected at $45B in 2026 sales. Semaglutide at $39.5B. Market analysis of the $84.5B GLP-1 pharmaceutical landscape.
Complete guide to managing nausea on semaglutide and tirzepatide: why it happens, how long it lasts, foods that help, medications like Zofran, and when to call your doctor.
The FLOW trial was stopped early because semaglutide worked so well for kidney disease. What the data shows and what it means for millions with CKD.
The landmark FLOW trial showed semaglutide reduced major kidney events and death in diabetic kidney disease. Published in NEJM, stopped early for efficacy.
Navigate GLP-1 insurance in 2025: Medicare/Medicaid coverage by state, commercial plan restrictions, prior auth strategies, appeal tactics, and manufacturer savings programs up to…
GLP-1 insurance coverage timeline 2026: Medicare Bridge $50/month copay, Medicaid expansion, commercial plan trends, and the prior authorization playbook.
Strategies for getting GLP-1 medications covered by insurance, manufacturer savings programs, and alternative options when coverage fails.
Complete guide to injecting semaglutide and tirzepatide: best injection sites, rotation patterns, preparation steps, and techniques for reducing pain and anxiety.
New data suggests GLP-1 drugs may reduce inflammation markers and autoimmune disease risk. Here
Semaglutide dramatically improved symptoms and quality of life in heart failure patients. What the STEP-HFpEF trial means for millions living with HFpEF.
GLP-1 medications may help gout by lowering uric acid levels. The obesity-gout connection, research on semaglutide and uric acid, and what patients report.
Users report GLP-1s curb gambling and shopping urges. We analyze the anecdotal reports, dopamine science, and why no clinical trials exist yet.
Reports of gambling urges disappearing on GLP-1 medications. The dopamine connection, viral stories, and what researchers think is happening.
Why rapid weight loss from semaglutide and tirzepatide increases gallstone risk. Symptoms to watch for, when to pause treatment, and whether you can restart after gallbladder surgery.
Food noise is the constant mental chatter about eating. Here
Semaglutide shows remarkable results for MASH (fatty liver disease). What the ESSENCE trial found and why FDA granted Breakthrough Therapy designation.
Complete GLP-1 eligibility guide: BMI requirements, qualifying conditions, Medicare coverage starting July 2026, insurance criteria, and who does not qualify. Every threshold explained with…
Complete guide to GLP-1 medication interactions with insulin, sulfonylureas, birth control, levothyroxine, warfarin, and alcohol. Based on FDA labels and 2025 ADA guidelines.
Does semaglutide help or worsen depression? A 100,000-person Swedish study, FDA safety reviews, and every major finding on GLP-1 medications and mental health — sourced and explained.
The EVOKE trial of semaglutide for Alzheimer
Complete GLP-1 pricing guide for 2026: Medicare Bridge at $50/mo, oral Wegovy at $149, compounded options, insurance, and manufacturer savings programs. Every price sourced.
How to evaluate compounding pharmacies for semaglutide and tirzepatide. 503A vs 503B explained, PCAB accreditation, COA verification, FDA warning signs, and 15 questions to ask before…
The truth about compounded GLP-1 medications. What we know about safety, quality concerns, and how to minimize risk.
Semaglutide reduced cocaine self-administration by 26% in rats and cocaine-seeking by 62%. We analyze the University of Gothenburg study and $2.7M UTHealth trial.
How GLP-1 weight loss medications may improve chronic pain conditions. The obesity-pain connection, anti-inflammatory effects, and what patients report.
When Oprah and other celebrities started talking openly about weight loss medications, the conversation changed. The cultural shift from secret shame to mainstream acceptance.
A study of 680,000+ patients found semaglutide users were 44-60% less likely to develop cannabis use disorder. We break down the Wang et al. 2024 findings.
A 2024 study found 44% lower cannabis use among patients on GLP-1 medications. What the research shows about marijuana, dopamine, and these drugs.
Rapid weight loss reduces bone density, but major GLP-1 trials show no increase in fracture events. The SELECT trial, AAOS 2026 data, and what the evidence actually says about bone health…
Weight loss reduces AFib burden significantly. How GLP-1 medications may help atrial fibrillation through weight loss and beyond.
Some people report reduced enjoyment of food, hobbies, and life on GLP-1 medications. What does the science say about this concern?
The EVOKE trials testing semaglutide for Alzheimer
A major JAMA Psychiatry study found 50-56% lower alcohol use disorder among GLP-1 patients. The science behind why Ozempic makes people drink less.
Can you drink alcohol on Ozempic or Zepbound? The science on GLP-1 alcohol interactions: hypoglycemia risk, slower metabolism, reduced cravings, and liver protection research.
GLP-1 medications reduce alcohol cravings by 41%, decrease smoking urge, and show signals across multiple substance use disorders. Complete evidence review.
Foundayo, Ozempic tablets, CagriSema, Wegovy 7.2mg — the options are expanding faster than ever.
Evidence review of the FLOW trial of semaglutide for diabetic chronic kidney disease.
Full breakdown of the FDA
Full timeline of how the FDA ended the semaglutide and tirzepatide shortages and reshaped the GLP-1 market.
Fact check of the SURMOUNT-5 head-to-head trial comparing tirzepatide to semaglutide.
Fact check on
Fact check comparing oral Wegovy to injectable Wegovy for weight management.
Fact check on the GLP-1 thyroid cancer black box warning and actual human risk data.
Fact check on GLP-1 muscle loss claims versus the actual body composition trial data.
Fact check on GLP-1 birth defect claims circulating on social media.
Fact check on GLP-1 medications for alcohol use disorder — what evidence supports the claim.
Fact check on the current legal status of compounded tirzepatide post-shortage.
Fact check on whether compounded semaglutide is really as effective as brand-name Wegovy.
Fact check of the viral
Analysis of employer health plan coverage for GLP-1 medications in 2026.
Complete investigation into which compounding pharmacies are still legally operating post-crackdown.
Current compounded GLP-1 pricing vs. brand-name cash-pay programs in 2026.
Evidence review of the CagriSema combination therapy trials and its competitive positioning vs tirzepatide.
CagriSema combines semaglutide with cagrilintide (amylin analog). Phase 3 results expected 2026, targeting ~25% weight loss. Full mechanism and trial analysis.
CagriSema combines semaglutide with cagrilintide (amylin analog). REDEFINE 1: 22.7% weight loss at 68 weeks, 60% lost 20%+. NDA filed December 2025. Complete data breakdown.
Complete implementation timeline for the CMS BALANCE Model and expanded Medicare GLP-1 coverage.
On December 20, 2024, the FDA approved Zepbound as the first-ever medication for obstructive sleep apnea. Here
What happens when you stop semaglutide or tirzepatide? We analyze the STEP 1 extension, SURMOUNT-4, and real-world data on weight regain and prevention strategies.
Everything you need to know about tirzepatide (Mounjaro/Zepbound). How it works, dosing, what to expect, and why it
Why do Ozempic and Wegovy cause rotten egg burps? The science of delayed gastric emptying, hydrogen sulfide, and evidence-based relief strategies.
Head-to-head comparison of semaglutide and tirzepatide. Efficacy, side effects, cost, and who each medication works best for.
Everything you need to know about semaglutide. How it works, what to expect, dosing, side effects, and results from clinical trials.
Ozempic requires a valid prescription in the US. Here
Men on semaglutide report their penis
Rapid GLP-1 weight loss can cause facial volume loss, sagging skin, and premature aging. Here
Thousands report strange, vivid dreams on semaglutide. Shopping with Clint Eastwood, robbing museums with celebrities. Here
Randomized trial data confirms semaglutide reduces alcohol consumption. The neuroscience of why GLP-1 drugs decrease drinking—verified with sources.
Oral semaglutide (Rybelsus) has 0.4-1% bioavailability vs. 89% for injectable. Here
Novo Nordisk has filed 111+ lawsuits against compounding pharmacies and telehealth companies. Track every case, outcome, and what it means for compounded semaglutide.
Retatrutide delivers 28.7% weight loss in Phase 3. Amycretin hits 22%. Orforglipron offers needle-free daily pill. Complete trial data on what
GLP-1 delivery methods compared. Needles vs pills vs drops. Pros, cons, and which format fits your lifestyle.
The exact process from quiz to delivery. How telehealth GLP-1 prescriptions work, what to expect, and how long it takes.
Weight loss stopped on Ozempic? Research shows plateaus typically occur around 60-68 weeks. Here
Research shows GLP-1 medications can increase testosterone levels in men with obesity by 18% on average. Here
Why does food taste different on semaglutide? New research shows GLP-1 drugs actually change taste bud gene expression and brain response to sweetness.
Researchers are calling GLP-1 medications a potential paradigm shift for addiction treatment. What the 12+ clinical trials mean for the future of treating compulsive behaviors.
The raw ingredient for a month of Ozempic costs under $50. So why does a prescription cost $1,000+? Breaking down the GLP-1 pricing chain with sources.
Can semaglutide reduce opioid cravings? Penn State researchers found a 40% reduction in cravings in early trials. Here
Comprehensive analysis of body composition data from STEP, SURMOUNT, and SURPASS trials. What DXA and MRI studies reveal about semaglutide and tirzepatide effects on lean mass.
Semaglutide received FDA approval for MASH in August 2025—the second drug ever approved for fatty liver disease. Phase 3 trial data, tirzepatide pipeline, and what it means.
Is GLP-1 hair loss real? We reviewed every FAERS analysis, cohort study, and dermatology paper. Here
Exenatide and liraglutide trials for alcohol and cocaine showed mixed results. Why researchers think semaglutide
Complete chronological history of GLP-1 medication FDA approvals. From Byetta (2005) to today
FDA and EMA investigations, FAERS data, WHO database analysis, and controlled studies on semaglutide and mental health. The complete picture with sources.
The FDA declared semaglutide and tirzepatide shortages resolved. Here
GLP-1 receptors in the VTA, nucleus accumbens, and prefrontal cortex may explain why these drugs affect cravings. A visual guide to the neuroscience.
Can Ozempic help binge eating disorder? The research on GLP-1 medications for BED and compulsive eating patterns.
If GLP-1s dampen the reward system, could they reduce pleasure from everything—not just food and drugs? What we know about anhedonia risk.
The first randomized controlled trial of semaglutide for alcohol use disorder is here. We break down exactly what the February 2025 JAMA Psychiatry study found.
Your complete prep list before starting GLP-1 treatment. Documents, supplies, questions to ask, and how to set yourself up for success.
How to spot sketchy GLP-1 telehealth providers. Red flags, warning signs, and what legitimate providers do differently.
Practical solutions for GLP-1 nausea. What causes it, when it improves, and 8 strategies that actually work.
The quick primer on GLP-1 medications. What they are, how they work, and whether they
GLP-1 eligibility explained. BMI requirements, medical conditions, and common myths busted. Find out if you qualify.
Real GLP-1 prices from real providers. What you
Practical fixes for GLP-1-related constipation. Why it happens and what to do about it.
fMRI brain imaging reveals how GLP-1 medications reduce food cravings and intrusive food thoughts. Primary research from Nature Medicine and clinical trials.
Day-by-day guide to your first week on GLP-1 medication. What
The FDA sent 50+ warning letters to GLP-1 compounders in September 2025. We
Complete analysis of the EVOKE and EVOKE+ Phase 3 trials. Semaglutide didn
FDA testing found compounded semaglutide potency ranging 42-170% of labeled dose. FAERS reports 442 adverse events. Here
Independent lab testing of compounded semaglutide found products ranging from 42% to 170% of labeled potency. Here
FDA testing data, Novo Nordisk analyses, and independent assays reveal wide potency variation in compounded semaglutide—from 0% to over 120% of labeled strength.
Which celebrities have actually admitted to using Ozempic, Wegovy, or Mounjaro? We tracked down the direct quotes — no speculation, just confirmed statements.
Understand the FDA
The Wegovy pill label, read for patients: empty stomach, 4-ounce water limit, 30-minute wait, the 1.5 to 25 mg dose steps, and how it differs from Rybelsus.
Mazdutide (Xinermei) is approved in China for obesity and type 2 diabetes. GLORY and DREAMS trial data, the US Phase 2, and why it isn
Where generic semaglutide is sold in 2026: Canada, India and Brazil launch dates, prices where reported, China
What the Foundayo label says: the April 2026 approval, dose steps from 0.8 to 17.2 mg, no food rules, the boxed warning, and interactions that change dosing.
How FDA
A step-by-step guide to FDA
FDA found patients injecting 5 to 20 times their compounded semaglutide dose. Here
How to read a certificate of analysis for compounded semaglutide or tirzepatide: identity, potency, purity, endotoxin, sterility, and what to ask your pharmacy.
Ecnoglutide is now approved in China, semaglutide copies are coming, and Hengrui
Eloralintide, petrelintide and cagrilintide alone are in Phase 3. Their Phase 2 weight loss, side effects and trial timelines, read from primary sources.
Eli Lilly plans a type 2 diabetes application for orforglipron based on the phase 3 ACHIEVE program. What is known about the program and why the indication matters.
A complete dated timeline of the GLP-1 compounding wind-down, from 2022 shortage status through the FDA
America
What the evidence supports on GLP-1 receptor agonists, delayed gastric emptying, and pulmonary aspiration risk during anaesthesia — including the FDA-required study.
A reading of the postmarketing requirements in the FDA approval letter for Foundayo (orforglipron), including the 15-year MTC registry and aspiration study.
An explainer on the FDA Commissioner
A September 2026 status tracker of GLP-1 litigation: Lilly v. Empower, Lilly v. Strive, the Strive antitrust dismissal, Novo v. Hims, and telehealth suits.
Foundayo was approved 50 days after filing and 294 days ahead of its PDUFA date — the fastest new molecular entity approval since 2002. How it happened.
A breakdown of the ATTAIN-1 and ATTAIN-2 trials supporting FDA approval of orforglipron (Foundayo), including efficacy, adverse events, and study limits.
A primary-source annotation of the FDA
The public weight-loss page describes prescription and home delivery but publishes no treatment price. Request the full initial bill, recurring medication and evaluation charges in writing before enrolling.
Important: Prices and program access may change. Compounded GLP-1 drugs are not FDA-approved. A medical evaluation is required; a prescription is not guaranteed. Some links are paid affiliate referrals and may earn this publication a commission. Check the current program terms, licensure, and fees directly before payment.